<table>
<thead>
<tr>
<th>Year</th>
<th>Milestones</th>
</tr>
</thead>
<tbody>
<tr>
<td>1992</td>
<td>• CPDR established by Act of Congress</td>
</tr>
</tbody>
</table>
| 1993 | • CPDR Basic Science Research Program established at the USU-Department of Surgery with Norman Rich, MD and COL David McLeod  
• Collaborative program with AFIP initiated for molecular bio-specimens (DNA and RNA bank)  
• Started the multi-disciplinary translational research program in prostate cancer |
| 1994 | • CPDR awarded prestigious “CaPCure” research award-Washington Post dubs award “prostate cancer Oscar”.  
• CPDR reports p53 and AR discoveries in advanced prostate cancer  
• Started urology resident rotation in cancer molecular biology |
| 1995 | • CPDR researchers first to report in JAMA that African American men have higher PSA values  
• CPDR defines the role of p53 in prostate cancer progression and gene therapy strategies  
• CPDR research recognized in media and at scientific meetings |
| 1996 | • Started the multi-center tri-service prostate cancer database  
• Published series of reports in leading journals on p53, bcl-2 and K1-67 biomarkers  
• CPDR basic science program acquires cutting edge technologies (LCM, Capillary Sequencer and Real time PCR machine) for gene discovery projects |
| 1997 | • Developed optimized PSA screening guidelines for African American men, published in NEJM,-featured on ABC News, CNN and other media  
• Dr. Judd W. Moul, CPDR Director awarded prestigious “Gold Cytoscope Award” from the AUA, the highest recognition given to an American Urologist |
| 1998 | • Developed internet-based prognostic model for prostate cancer  
• Discovery of a novel prostate specific non-coding RNA gene, PCGEM1  
• CPDR defines a new tumor suppressor locus on chromosome 6q |
| 1999 | • Grand opening of the CPDR Headquarters and Research Center in Rockville, MD  
• CPDR founder COL David G. McLeod named president of American Foundation for Urologic Disease  
• CPDR establishes collaboration with Human Genome Sciences and reports discovery of a prostate specific gene PSGR |
| 2000 | • Opening of CPDR Comprehensive Prostate Disease Clinical Care Center at WRAMC-entire ward devoted to clinical care and research on prostate cancer  
• CPDR awarded first NIH RO1 grant to study the prostate cancer gene PCGEM1  
• CPDR establishes CRADA with Avalon for spectral karyotyping of prostate cancer cells |
| 2001 | • Established the Prostate Cell Center for the development of new cell culture models  
• CPDR reports multiple discoveries of novel prostate cancer genes in leading journals  
• CPDR reports the male hormone transcriptome database using SAGE technology |
| 2002 | • CPDR celebrates the ten year anniversary of its establishment  
• CPDR receives two DoD/CDMRP grants focusing on: PSGR gene and an internet accessible prognostic nomogram  
• CPDR multi-center database completes reports for multiple studies on racial disparity |
| 2003 | • CPDR reports a comprehensive study of diagnostic and prognostic potential of circulating tumor cells  
• CPDR reports a novel prostate selective gene, PMEPA1, as a novel regulator of AR  
• CPDR develops prostate cancer gene expression database  
• CPDR establishes the Multi-Disciplinary Prostate Cancer Clinic  
• Started the DoD’s first Prostate Cancer Quality of Life Study for military beneficiaries |
| 2004 | • CPDR receives an RO1 grant from NIH to study the cell-specific gene expression signatures of prostate cancer  
• First patent issued to CPDR on prostate cancer specific gene PCGEM1 |
Dr. Judd W. Moul, Director of CPDR, retires from the military and assumes Chief position at Urology Department, Duke University

2005
- CPDR defines the most common defect in prostate cancer (ERG)
- COL David G. McLeod named Director and Dr. Shiv Srivastava named Co-Director of CPDR
- CPDR initiates a program in engineered mouse models to study functions of prostate cancer genes

2006
- CPDR discovery, a robust prostate cancer gene panel, is licensed to Gen-Probe Inc. and CRADA is established
- CPDR receives an RO1 grant to study the PMEPA1 gene a novel regulator of androgen receptor

2007
- Dr. Shiv Srivastava, Co-Director, receives the James Leonard Award for excellence in clinical research from the USU
- CPDR is receives a new DoD-PCRP grant to study new aspects of the ERG oncogene function

2008
- CPDR reports a new mechanism and therapeutic potential of ERG oncogene involving C-MYC
- CPDR receives an award from DoD/CDMRP to train new generation of researchers under the HBCU Students Summer Research Training Program

2009
- COL David G. McLeod, Director, receives the distinguished Contribution Award, for his leadership and direction of urology programs at the USU Medical School and Walter Reed Hospital, and for his mentorship to civilian and military personnel
- CPDR develops the first monoclonal antibody for evaluating ERG oncoprotein in prostate cancer
- CPDR and Gen-Probe report prognostic value of Urine PCA3 test

2010
- CPDR designated as a Center of Excellence by DoD under the USU
- CPDR reports the first evaluation of ERG oncoprotein in prostate cancer

2011
- Donald Coffey delivers the Distinguished Lecture at CPDR on prostate cancer
- The CPDR’s ERG monoclonal antibody is licensed by the Biocare Medical Inc. for world-wide distribution for pathologic evaluations of prostate cancer
- CPDR provides commentary on PCA3 test in the Nature Reviews Urology
- CPDR receives a competitive renewal of the RO1 grant from NIH to continue ERG oncogene studies

2012
- CPDR establishes an Inter-Agency Agreement with the NCI EDRN
- CPDR publishes first review on ERG oncoprotein in Nature Review Urology
- CPDR publishes a definitive study of differences of ERG frequency between Caucasian and African American patients

2013
- CPDR receives 3 grant awards: DoD/PCRP-Health Disparity; USU-JOTT and MCI
- CPDR launches CRADA with the Genomic Health Inc and Berg Pharma companies
- CPDR develops new research collaborations with NCI prostate cancer group

2014
- CPDR team working with the Genomic Health Inc. has successfully completed the independent validation of the Oncotype DX prognostic test, the result was published in the European Urology
- CPDR received 3 grant awards: DoD/PCRP-HBCU Training Award, MCC- Translational Research Fellowship Award, and USU-JOTT IP Development Award

2015
- CPDR ground-breaking discovery of a recurrent genomic deletion in African American prostate cancers reported in EBioMedicine represents a paradigm shift in evaluations of ethnicity informed cancer genomes with impact on precision medicine
- CPDR received two grant awards: DoD/PCRP-Health Disparity; and from CCR/NCI-MCC
- The first CPDR patent application is published on novel inhibitors of ERG positive cancers